Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . A SINO BIOPHARMACEUTICAL LIMITED 中國 生物 製藥 有限公司 ( Incorporated in the Cayman Islands with limited liability ) Website : www.sinobiopharm.com ( Stock code : 1177 ) FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 31 MARCH , 2021 FINANCIAL HIGHLIGHTS For the three months ended 31 March , 2021 , the Group recorded the following unaudited results : Revenue was approximately RMB7,243 million , an increase of approximately 16.4 % over the same period last year ; Profit attributable to the owners of the parent was approximately RMB1,913.50 million , an increase of approximately 118.5 % over the same period last year ; Basic earnings per share attributable to the owners of the parent were approximately RMB10.19 cents , an increase of approximately 118.7 % over the same period last year ; Sales of new products ( Note ) accounted for approximately 47.4 % of the Group's total revenue ; amounted to approximately RMB3,433.69 million , an increase of approximately 67.0 % over the same period last year ; Sales of oncology medicines amounted to approximately RMB2,638.42 million , an increase of approximately 31.8 % over the same period last year ; and Cash and bank balances as at 31 March , 2021 was approximately RMB7,932.11 million . The Board of the Company has declared the payment of a quarterly dividend of HK2 cents per share for the three months ended 31 March , 2021 . Note : Products launched within five years . 1